Switching therapies: considerations around alemtuzumab

Are you a switcher? There are several issues that need to be resolved regarding safety. #MSBlog #MSResearch

"The following are my slides from a talk I gave last night at the SINS meeting in Santiago, Chile. The focus of the talk was an informal discussion of the issues and considerations in relation to switching MSers from one DMT to alemtuzumab. As you are aware from previous posts on the blog that there are many issues that still need to be resolved by doing studies to assess the safety and timing of starting alemtuzumab. My biggest concerns relate to switching patients at high-risk of PML from natalizumab to alemtuzumab and switching patients who have been on fingolimod for a long period of time to alemtuzumab."




CoI: multiple

Labels: , , , ,